Dermira, Inc. (DERM): Price and Financial Metrics
GET POWR RATINGS... FREE!
DERM Stock Price Chart Interactive Chart >
DERM Price/Volume Stats
| Current price | $3.95 | 52-week high | $10.20 |
| Prev. close | $4.30 | 52-week low | $3.04 |
| Day low | $3.95 | Volume | 28,100 |
| Day high | $4.49 | Avg. volume | 55,009 |
| 50-day MA | $4.31 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 68.40M |
Dermira, Inc. (DERM) Company Bio
Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. The company was founded in 2010 and is based in Menlo Park, California.
Latest DERM News From Around the Web
Below are the latest news stories about Journey Medical Corp that investors may wish to consider to help them evaluate DERM as an investment opportunity.
VYNE Therapeutics Offloads Its Topical Minocycline Assets To Journey Medical In $450M+ DealJourney Medical Corporation (NASDAQ: DERM) has acquired Molecule Stabilizing Technology (MST) franchise, including Amzeeq (minocycline) topical foam and Zilxi (minocycline) topical foam from VYNE Therapeutics Inc (NASDAQ: VYNE) The transaction includes cash payments of million and potential milestones of up to 0 million. Approved by the FDA nearly 50 years ago, minocycline is a well-established molecule that has been prescribed, in oral formulation, over 30 million times in the past decade. Amze |
VYNE Therapeutics Divests Topical Minocycline AssetsTransaction includes cash payments of $25 million and potential milestones of up to $450 million Sale aligns with VYNE’s strategic plan; proceeds will be used to fund development of Company’s immuno-inflammatory pipeline BRIDGEWATER, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has sold its Molecule Stabilizing Technology (MST™) franchise, including AMZEEQ® (minocycline) topical foam, 4%, and ZILXI® (minocycline) |
Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.Franchise includes AMZEEQ® for the treatment of acne and ZILXI® for the treatment of rosacea, and a development-stage dermatology program (FCD105) along with the MST proprietary platform Acquisition expands Journey Medical’s portfolio to nine marketed dermatology products East West Bank Credit agreement expanded to $30.0 million SCOTTSDALE, Ariz., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focus |
How the stocks of 6 Arizona companies fared after going public in 2021Six Arizona companies went public this year, including ones in the health care, proptech and car wash industries. See how their shares performed since debuting on public markets. |
Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate HighlightsGenerated record net revenues of $19.6 million for the third quarter of 2021 Completed initial public offering of common stock and raised $31.2 million in net proceeds SCOTTSDALE, Ariz., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent |
DERM Price Returns
| 1-mo | 1.80% |
| 3-mo | -25.33% |
| 6-mo | -51.95% |
| 1-year | N/A |
| 3-year | -59.78% |
| 5-year | -85.56% |
| YTD | -26.58% |
| 2021 | N/A |
| 2020 | 0.00% |
| 2019 | 110.85% |
| 2018 | -74.15% |
| 2017 | -8.31% |
Continue Researching DERM
Want to do more research on NA's stock and its price? Try the links below:NA (DERM) Stock Price | Nasdaq
NA (DERM) Stock Quote, History and News - Yahoo Finance
NA (DERM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...